CN¥264.41
1.91%
Shanghai, Sep 30, 03:00 pm CST.
ISIN
KYG1146Y1017
Symbol
688235

Beone Medicines-h Target price 2026 - Analyst rating & recommendation

Beone Medicines-h Classifications & Recommendation

Buy
92%
Hold
8%

Beone Medicines-h Price Target

Target Price CN¥369.84
Price CN¥264.41
Potential
Number of Estimates 8
8 Analysts have issued a price target Beone Medicines-h 2027 . The average Beone Medicines-h target price is CN¥369.84. This is higher than the current stock price. The highest price target is
CN¥476.81 80.33%
register free of charge
, the lowest is
CN¥308.66 16.73%
register free of charge
.
A rating was issued by 12 analysts: 11 Analysts recommend Beone Medicines-h to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Beone Medicines-h stock has an average upside potential 2027 of . Most analysts recommend the Beone Medicines-h stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Billion CN¥ 38.23 47.04
40.46% 23.06%
EBITDA Margin 9.23% 18.34%
168.74% 98.60%
Net Margin 3.82% 12.89%
120.89% 237.32%

7 Analysts have issued a sales forecast Beone Medicines-h 2026 . The average Beone Medicines-h sales estimate is

CN¥47.0b
unlock
. This is
9.58% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CN¥50.4b 17.44%
unlock
, the lowest is
CN¥44.5b 3.74%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 CN¥38.2b 40.46%
2026
CN¥47.0b 23.06%
unlock
2027
CN¥54.3b 15.48%
unlock
2028
CN¥61.1b 12.48%
unlock
2029
CN¥62.3b 1.96%
unlock
2030
CN¥69.3b 11.22%
unlock
2031
CN¥75.2b 8.61%
unlock
2032
CN¥82.4b 9.45%
unlock
2033
CN¥89.4b 8.56%
unlock

7 Beone Medicines-h Analysts have issued a net profit forecast 2026. The average Beone Medicines-h net profit estimate is

CN¥6.1b
unlock
. This is
41.56% higher
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
CN¥7.1b 65.47%
unlock
, the lowest is
CN¥4.9b 14.68%
unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 CN¥1.5b 129.34%
2026
CN¥6.1b 314.94%
unlock
2027
CN¥8.7b 42.73%
unlock
2028
CN¥11.2b 29.78%
unlock
2029
CN¥151b 1,243.91%
unlock
2030
CN¥188b 24.65%
unlock
2031
CN¥187b 0.46%
unlock
2032
CN¥263b 40.42%
unlock
2033
CN¥303b 15.36%
unlock

Net Margin

2025 3.82% 120.89%
2026
12.89% 237.32%
unlock
2027
15.93% 23.58%
unlock
2028
18.38% 15.38%
unlock
2029
242.22% 1,217.85%
unlock
2030
271.47% 12.08%
unlock
2031
248.80% 8.35%
unlock
2032
319.20% 28.30%
unlock
2033
339.20% 6.27%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share CN¥ 0.98 4.13
126.92% 321.43%
P/E 64.10
EV/Sales 5.44

7 Analysts have issued a Beone Medicines-h forecast for earnings per share. The average Beone Medicines-h EPS is

CN¥4.13
unlock
. This is
47.50% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
CN¥4.82 72.14%
unlock
, the lowest is
CN¥3.34 19.29%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 CN¥0.98 126.92%
2026
CN¥4.13 321.43%
unlock
2027
CN¥5.89 42.62%
unlock
2028
CN¥7.64 29.71%
unlock
2029
CN¥102.70 1,244.24%
unlock
2030
CN¥128.01 24.64%
unlock
2031
CN¥127.42 0.46%
unlock
2032
CN¥178.93 40.43%
unlock
2033
CN¥206.42 15.36%
unlock

P/E ratio

Current 94.43 133.16%
2026
64.10 32.12%
unlock
2027
44.91 29.94%
unlock
2028
34.60 22.96%
unlock
2029
2.57 92.57%
unlock
2030
2.07 19.46%
unlock
2031
2.08 0.48%
unlock
2032
1.48 28.85%
unlock
2033
1.28 13.51%
unlock

Based on analysts' sales estimates for 2026, the Beone Medicines-h stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.97 29.93%
2026
5.44 8.80%
unlock
2027
4.72 13.40%
unlock
2028
4.19 11.09%
unlock
2029
4.11 1.92%
unlock
2030
3.70 10.08%
unlock
2031
3.40 7.93%
unlock
2032
3.11 8.64%
unlock
2033
2.86 7.89%
unlock

P/S ratio

Current 6.61 25.64%
2026
6.04 8.74%
unlock
2027
5.23 13.40%
unlock
2028
4.65 11.10%
unlock
2029
4.56 1.92%
unlock
2030
4.10 10.09%
unlock
2031
3.77 7.93%
unlock
2032
3.45 8.64%
unlock
2033
3.18 7.89%
unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today